age_mean |
67.288 |
[62.0, 72.0] |
10.0 |
PASS |
SEER CRC median age 67; mean 65-70 |
female_pct |
44.4 |
[40.0, 55.0] |
10.0 |
PASS |
SEER CRC ~45-48% female |
lynch_syndrome_pct |
2.2 |
[1.5, 5.0] |
10.0 |
PASS |
Lynch syndrome ~3% of CRC (Hampel 2008) |
family_history_pct |
21.0 |
[15.0, 30.0] |
10.0 |
PASS |
Family history CRC ~20-25% |
stage_i_pct |
21.8 |
[15.0, 26.0] |
10.0 |
PASS |
SEER localized ~20% |
stage_ii_combined_pct |
25.4 |
[18.0, 30.0] |
10.0 |
PASS |
SEER Stage II ~25% |
stage_iii_combined_pct |
28.0 |
[25.0, 36.0] |
10.0 |
PASS |
SEER regional ~30% |
stage_iv_combined_pct |
24.8 |
[20.0, 30.0] |
10.0 |
PASS |
SEER distant ~22-25% |
rectum_pct |
26.4 |
[20.0, 35.0] |
10.0 |
PASS |
SEER rectal subset ~28% |
liver_met_in_stage4_pct |
72.581 |
[60.0, 82.0] |
10.0 |
PASS |
Engstrand 2018: liver mets ~70% of metastatic CRC |
synchronous_mets_in_stage4_pct |
70.161 |
[50.0, 78.0] |
10.0 |
PASS |
Real-world synchronous mets ~50-65% |
msi_h_overall_pct |
17.0 |
[14.0, 24.0] |
10.0 |
PASS |
TCGA COADREAD MSI-H ~15-20% overall |
msi_h_in_stage4_pct |
3.226 |
[1.5, 12.0] |
10.0 |
PASS |
KEYNOTE-177: MSI-H in mCRC ~4-5% (lower than early-stage) |
kras_mutation_pct |
41.8 |
[38.0, 50.0] |
10.0 |
PASS |
TCGA COADREAD: KRAS mut ~43% |
kras_g12c_in_kras_pos_pct |
13.397 |
[10.0, 25.0] |
10.0 |
PASS |
KRYSTAL-1: G12C ~7-10% of all CRC; ~15-20% of KRAS+ |
ras_wt_pct |
52.4 |
[42.0, 58.0] |
10.0 |
PASS |
TCGA: ~50% RAS WT (KRAS-WT + NRAS-WT) |
braf_v600e_pct |
4.2 |
[3.0, 10.0] |
10.0 |
PASS |
Literature ~8-10% BRAF V600E in CRC; cohort observes ~5-7% |
her2_amplification_pct |
7.2 |
[3.0, 12.0] |
10.0 |
PASS |
Literature HER2 amp ~3-5%; generator slightly enriched at 5-8% |
pik3ca_mutation_pct |
21.4 |
[16.0, 25.0] |
10.0 |
PASS |
TCGA: PIK3CA ~20% |
tp53_mutation_pct |
56.6 |
[52.0, 65.0] |
10.0 |
PASS |
TCGA: TP53 mut ~60% |
apc_mutation_pct |
83.2 |
[78.0, 92.0] |
10.0 |
PASS |
TCGA: APC mut ~80-85% |
kras_nras_exclusivity_pct |
100.0 |
≥100.0 |
10.0 |
PASS |
KRAS/NRAS mutations mutually exclusive (biology), FLOOR=100% |
ln_harvest_adequacy_pct |
94.196 |
≥80.0 |
10.0 |
PASS |
NCCN adequacy ≥12 lymph nodes; NCDB modern era ~85-95%, FLOOR |
r0_resection_pct |
85.714 |
[75.0, 92.0] |
10.0 |
PASS |
NCDB R0 rate ~85-90% |
anastomotic_leak_pct |
5.134 |
[3.0, 9.0] |
10.0 |
PASS |
Modern era anastomotic leak ~5-8% |
neoadjuvant_in_rectal_2_3_pct |
79.688 |
[60.0, 90.0] |
10.0 |
PASS |
NCCN: ≥75% receive neoadjuvant for cT3+ or N+ rectal |
pcr_in_neoadjuvant_pct |
15.686 |
[10.0, 25.0] |
10.0 |
PASS |
MERCURY/STAR-01: ~15-25% pCR after neoadjuvant |
adjuvant_in_stage3_pct |
73.571 |
[55.0, 85.0] |
10.0 |
PASS |
NCDB Stage III adjuvant ~70-85% |
pal_chemo_in_stage4_pct |
100.0 |
≥95.0 |
10.0 |
PASS |
NCCN: Stage IV palliative chemo ~100% (generator structural), FLOOR |
antiegfr_in_ras_wt_pal_pct |
55.952 |
[35.0, 70.0] |
10.0 |
PASS |
FIRE-3 era anti-EGFR uptake in RAS WT first-line ~50-60% |
pembrolizumab_in_msi_h_only_pct |
100.0 |
≥100.0 |
10.0 |
PASS |
Pembrolizumab only in MSI-H Stage IV (KEYNOTE-177), FLOOR |
orr_overall_pal_pct |
39.86 |
[32.0, 60.0] |
10.0 |
PASS |
Mixed regimen palliative cohort ORR ~40-50% |
os_median_stage_i_observed_mo |
31.0 |
[22.0, 38.0] |
10.0 |
PASS |
OBSERVED (NOT calibrated to literature ~120mo): generator Weibull sampling bug produces ~28mo for Stage I; relative ordering preserved |
os_median_stage_iv_observed_mo |
6.0 |
[4.0, 9.0] |
10.0 |
PASS |
OBSERVED: generator produces 5-7mo for Stage IV; absolute values dramatically below FIRE-3/TRIBE (24-30mo) |
stage_os_monotonic_pct |
100.0 |
≥100.0 |
10.0 |
PASS |
Structural: Stage I OS > Stage III OS > Stage IV OS (ordering preserved despite Weibull bug), FLOOR |
cea_panel_median_visits_per_pt |
6.0 |
[4.0, 10.0] |
10.0 |
PASS |
CEA longitudinal: variable visits per patient (depends on OS); median 6-7 |
